查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1696278

日本糖尿病数位治疗市场 - 2025 至 2033 年

Japan Digital Therapeutics for Diabetes Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024 年日本糖尿病数位治疗市场规模达到 5,659 万美元，预计到 2033 年将达到 1.3644 亿美元，在 2025-2033 年预测期内的复合年增长率为 10.4%。

糖尿病的数位疗法是指基于证据的、软体驱动的干预措施，旨在管理和治疗糖尿病，主要着重于改善健康结果和透过科技管理病情。这些干预措施使用行动应用程式、穿戴式装置和连网平台等数位工具，为糖尿病患者提供个人化的治疗和支援。数位疗法利用从患者装置（如血糖仪、穿戴式装置或行动应用程式）收集的即时资料来持续监测血糖水平、体力活动、饮食和药物依从性。

市场动态：

驱动因素与约束因素

日本糖尿病盛行率上升推动糖尿病数位治疗市场成长

根据国际糖尿病联盟（IDF）统计，日本有1,100万成年人患有糖尿病。糖尿病的高盛行率与沉重的经济负担有关，这可归因于生活方式的改变和寿命的延长。日本是世界上老化程度最高的国家之一（29% 的人口为 65 岁或以上），这显着增加了糖尿病病例的数量。老年人更容易患第2型糖尿病，对慢性病管理的需求更高。

日本目前的糖尿病管理模式严重依赖频繁就医、注射胰岛素和身体检查。无论对于医疗保健系统还是患者来说，这都是昂贵且耗时的。随着糖尿病患者数量的增加，传统的方法已不足以应对日益增长的患者数量。行动应用程式、穿戴式装置（如连续血糖监测仪）和人工智慧驱动平台等数位解决方案可提供远端监控、个人化回馈和即时管理。这些技术有助于减少频繁就诊的需要，并允许患者更好地在家中追踪自己的健康状况。

随着越来越多的人被诊断出患有糖尿病，对数位化糖尿病管理等经济高效、可扩展且方便的解决方案的需求也日益增加。人口老化、高昂的医疗成本以及政府对数位健康科技的支持，共同构成了日本糖尿病管理市场的一个主要趋势。利用数位健康科技预防和治疗糖尿病是糖尿病管理的最新趋势。

资料隐私和安全问题阻碍了日本糖尿病数位疗法市场的成长

日本製定了《个人资讯保护法》（APPI）等严格的资料保护法，对个人和健康资料的储存和共享设定了高标准。数位治疗公司必须遵守这些法规，以保护患者的敏感健康资讯。满足这些法规的复杂性增加了数位健康公司的开发和营运成本。

APPI 规定获取个人资料的公司需要获得患者的明确同意，这可能会延迟日本新的数位治疗解决方案的开发和部署。公司必须确保资料安全存储，并立即报告违规行为，这带来了合规性挑战。

由于担心隐私和滥用，许多日本患者可能不愿意与数位健康平台分享他们的健康资料。这种不信任可能会限制数位疗法的采用，尤其是当患者不确定他们的资料将如何被使用、共享或储存时。由于数位治疗解决方案连接到云端并依赖互联网进行即时资料共享，资料外洩或骇客攻击的风险增加。安全漏洞可能会暴露患者的医疗和个人资料，损害数位治疗提供者的声誉并导致法律后果。

目录

第一章：市场介绍和范围

  • 报告目标
  • 报告范围和定义
  • 报告范围

第 2 章：高阶主管见解与关键要点

  • 市场亮点和战略要点
  • 主要趋势和未来预测
  • 按产品类型分类的片段
  • 按应用程式截取的程式码片段
  • 最终用户的程式码片段

第 3 章：动态

  • 影响因素
    • 驱动程式
      • 日本糖尿病盛行率上升
      • 不断进步的技术
    • 限制
      • 资料隐私和安全问题
      • 监管挑战
    • 机会
      • 糖尿病数位治疗中的人工智慧
    • 影响分析

第四章：战略洞察与产业展望

  • 市场领导者和先驱者
    • 新兴先锋和杰出参与者
    • 拥有最大销售品牌的成熟领导者
    • 拥有成熟产品的市场领导者
  • 新兴创业公司和关键创新者
  • CXO 观点
  • 最新进展与突破
  • 案例研究/正在进行的研究
  • 日本监管和报销状况
  • 波特五力分析
  • 供应链分析
  • SWOT 分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态

第 5 章：糖尿病数位治疗市场（依产品类型）

  • 软体解决方案
    • 行动应用程式
    • 基于 Web 的解决方案
  • 硬体解决方案
    • 穿戴式装置
    • 连续血糖监测仪
    • 其他的

第 6 章：糖尿病数位治疗市场（按应用）

  • 1 型糖尿病
  • 2 型糖尿病
  • 糖尿病前期

第 7 章：糖尿病数位治疗市场（以最终用户划分）

  • 医院
  • 专科诊所
  • 家庭护理设置
  • 其他的

第 8 章：竞争格局与市场定位

  • 竞争概况和主要市场参与者
  • 市占率分析与定位矩阵
  • 策略伙伴关係、併购
  • 产品组合和创新的关键发展
  • 公司基准化分析

第九章：公司简介

  • Welldoc, Inc.
    • 公司概况
    • 产品组合
      • 产品描述
      • 产品关键绩效指标 (KPI)
      • 历史和预测产品销售量
      • 产品销售量
    • 财务概览
      • 公司收入
      • 地区收入份额
      • 收入预测
    • 关键进展
      • 合併与收购
      • 关键产品开发活动
      • 监管部门批准等
    • SWOT 分析
  • Omada Health Inc.
  • Glooko, Inc.
  • Azumio Inc.
  • Abbott Laboratories
  • Life Log Technology, Inc.
  • Dexcom, Inc.
  • Health2Sync
  • iHealth Labs Inc.
  • Medtronic plc

第 10 章：假设与研究方法

  • 资料收集方法
  • 数据三角测量
  • 预测技术
  • 数据验证和确认

第 11 章：附录

简介目录
Product Code: HCIT9374

The Japan digital therapeutics for diabetes market size reached US$ 56.59 million in 2024 and is expected to reach US$ 136.44 million by 2033, growing at a CAGR of 10.4% during the forecast period 2025-2033.

Digital therapeutics for diabetes refers to evidence-based, software-driven interventions designed to manage and treat diabetes, primarily focusing on improving health outcomes and managing the condition through technology. These interventions use digital tools, such as mobile apps, wearable devices and connected platforms, to provide personalized treatments and support for individuals with diabetes. Digital therapeutics leverage real-time data collected from patients' devices (such as glucose meters, wearables or mobile apps) to provide continuous monitoring of blood glucose levels, physical activity, diet and medication adherence.

Market Dynamics: Drivers & Restraints

The rising prevalence of diabetes in Japan driving the digital therapeutics for diabetes market growth

According to the International Diabetes Federation (IDF), 11 million adults in Japan have diabetes. The high prevalence of diabetes is associated with a significant economic burden and can be attributed to lifestyle changes and increased longevity. Japan's aging population, which is one of the oldest in the world (29% of the population is 65 years or older), significantly increases the number of diabetes cases. Older adults are more susceptible to Type 2 diabetes, leading to higher demands for chronic disease management.

The current diabetes management model in Japan is heavily reliant on frequent doctor visits, insulin injections and physical check-ups. This is costly and time-consuming, both for the healthcare system and for patients. As the number of diabetes patients rises, the traditional approach is proving insufficient to handle the increasing volume. Digital solutions like mobile apps, wearable devices (such as continuous glucose monitors) and AI-driven platforms offer remote monitoring, personalized feedback and real-time management. These technologies help reduce the need for frequent visits and allow patients to better track their health from home.

As more people are diagnosed with diabetes, the need for cost-effective, scalable and convenient solutions like digital diabetes management increases. The combination of an aging population, high healthcare costs and government backing for digital health technologies makes a key trend in Japan's diabetes management market. Using digital health technology to prevent and treat diabetes is the latest trend in diabetes management.

Data privacy and security concerns hampering the growth of Japan digital therapeutics for diabetes market

Japan has stringent data protection laws under the Act on the Protection of Personal Information (APPI), which sets high standards for the storage and sharing of personal and health data. Digital therapeutics companies must comply with these regulations to protect patients' sensitive health information. The complexity of meeting these regulations adds to the development and operational costs for digital health companies.

The APPI mandates that companies obtaining personal data need explicit consent from patients, which can delay the development and deployment of new digital therapeutic solutions in Japan. Companies must ensure data is securely stored and breaches are immediately reported, creating compliance challenges.

Many Japanese patients may be hesitant to share their health data with digital health platforms due to concerns about privacy and misuse. This mistrust can limit the adoption of digital therapeutics, especially if patients feel unsure about how their data will be used, shared or stored. As digital therapeutics solutions are connected to the cloud and rely on the internet for real-time data sharing, the risk of data breaches or hacking increases. A breach in security could expose patients' medical and personal data, damaging the reputation of the digital therapeutics provider and leading to legal ramifications.

Segment Analysis

The Japan digital therapeutics for diabetes market is segmented based on product type, application and end-user.

Product Type:

The software solutions in the product type segment are expected to dominate the Japan digital therapeutics for diabetes market with the highest market share

Software solutions including mobile apps and digital platforms can provide personalized diabetes management by using real-time data and AI-driven algorithms to deliver customized treatment recommendations. These solutions allow patients to track blood glucose levels, diet, physical activity and medication adherence daily, offering individualized feedback.

For instance, in March 2023, Health2Sync announced its latest version of the Health2Sync App integrates insulin data from Mallya Cap, the connected device dedicated to insulin pens developed by Biocorp and marketed in Japan by Novo Nordisk. This partnership realizes the first data integration of its kind and is expected to help patients on insulin treatment manage their health by capturing multiple data points, including insulin injection logs.

Software solutions, particularly mobile applications, are highly accessible and can be used on smartphones or tablets, allowing patients to manage their diabetes from anywhere. This convenience is especially beneficial for the aging population in Japan, many of whom are managing diabetes and prefer digital tools that offer self-monitoring and remote consultation features.

Competitive Landscape

The major Japan players in the digital therapeutics for diabetes market include Welldoc, Inc., Omada Health Inc., Glooko, Inc., Azumio Inc., Abbott Laboratories, Life Log Technology, Inc., Dexcom, Inc., Health2Sync, iHealth Labs Inc. and Medtronic plc among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Japan digital therapeutics for diabetes market report delivers a detailed analysis with 39 key tables, more than 26 visually impactful figures and 158 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Prevalence of Diabetes in Japan
      • 3.1.1.2. Rising Technological Advancements
    • 3.1.2. Restraints
      • 3.1.2.1. Data Privacy and Security Concerns
      • 3.1.2.2. Regulatory Challenges
    • 3.1.3. Opportunity
      • 3.1.3.1. Artificial Intelligence in Diabetes Digital Therapeutics
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Japan Regulatory and Reimbursement Landscape
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics

5. Digital Therapeutics for Diabetes Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Software Solutions*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 5.2.3. Mobile Apps
    • 5.2.4. Web-Based Solutions
  • 5.3. Hardware Solutions
    • 5.3.1. Wearable Devices
    • 5.3.2. Continuous Glucose Monitors
    • 5.3.3. Others

6. Digital Therapeutics for Diabetes Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Type-1 Diabetes*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Type-2 Diabetes
  • 6.4. Pre-Diabetes

7. Digital Therapeutics for Diabetes Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Specialty Clinics
  • 7.4. Homecare Settings
  • 7.5. Others

8. Competitive Landscape and Market Positioning

  • 8.1. Competitive Overview and Key Market Players
  • 8.2. Market Share Analysis and Positioning Matrix
  • 8.3. Strategic Partnerships, Mergers & Acquisitions
  • 8.4. Key Developments in Product Portfolios and Innovations
  • 8.5. Company Benchmarking

9. Company Profiles

  • 9.1. Welldoc, Inc.*
    • 9.1.1. Company Overview
    • 9.1.2. Product Portfolio
      • 9.1.2.1. Product Description
      • 9.1.2.2. Product Key Performance Indicators (KPIs)
      • 9.1.2.3. Historic and Forecasted Product Sales
      • 9.1.2.4. Product Sales Volume
    • 9.1.3. Financial Overview
      • 9.1.3.1. Company Revenue's
      • 9.1.3.2. Geographical Revenue Shares
      • 9.1.3.3. Revenue Forecasts
    • 9.1.4. Key Developments
      • 9.1.4.1. Mergers & Acquisitions
      • 9.1.4.2. Key Product Development Activities
      • 9.1.4.3. Regulatory Approvals, etc.
    • 9.1.5. SWOT Analysis
  • 9.2. Omada Health Inc.
  • 9.3. Glooko, Inc.
  • 9.4. Azumio Inc.
  • 9.5. Abbott Laboratories
  • 9.6. Life Log Technology, Inc.
  • 9.7. Dexcom, Inc.
  • 9.8. Health2Sync
  • 9.9. iHealth Labs Inc.
  • 9.10. Medtronic plc

LIST NOT EXHAUSTIVE

10. Assumption and Research Methodology

  • 10.1. Data Collection Methods
  • 10.2. Data Triangulation
  • 10.3. Forecasting Techniques
  • 10.4. Data Verification and Validation

11. Appendix

  • 11.1. About Us and Services
  • 11.2. Contact Us